Investment Thesis
BioAtla is a pre-revenue biotech company in critical financial distress with negative stockholders' equity of -$36.2M and liabilities exceeding total assets by 3.6x. With only $7.1M in cash and negative operating cash flow of $48.2M annually, the company has approximately 1.7 months of runway and faces imminent insolvency without significant capital infusion or immediate revenue generation.
Strengths
- YoY net income improving 14.6%, indicating management efforts to reduce burn rate
- EPS loss narrowing 29.9% YoY shows operational efficiency gains in pre-revenue phase
- Retained $7.1M in cash reserves despite ongoing losses and negative equity position
Risks
- Negative stockholders' equity of -$36.2M indicating technical insolvency and balance sheet deterioration
- Zero revenue with liabilities ($50M) nearly 4x total assets ($13.8M), signaling failed commercialization
- Current ratio of 0.37x reflects severe liquidity crisis and inability to meet near-term obligations
- Negative free cash flow of $48.2M annually with minimal runway—existential risk without emergency financing
- Pre-revenue biotech pipeline with uncertain clinical/commercial outcomes and extended R&D timelines
- 7 Form 4 insider filings in 90 days may indicate insider selling or loss of confidence
Key Metrics to Watch
- Cash burn rate trajectory and estimated months of runway to insolvency
- New financing announcements or partnership/licensing deals for asset monetization
- Revenue recognition from any clinical trial completions, regulatory approvals, or product launches
- Changes in insider transaction patterns and director/officer holdings
Financial Metrics
Revenue
0.0
Net Income
-59.6M
EPS (Diluted)
$-1.01
Free Cash Flow
-48.2M
Total Assets
13.8M
Cash
7.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-431.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.37x
Quick Ratio
0.37x
Debt/Equity
N/A
Debt/Assets
361.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T08:09:28.134156 |
Data as of: 2025-12-31 |
Powered by Claude AI